Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain
- 31 May 2007
- journal article
- Published by Elsevier BV in Molecular Immunology
- Vol. 44 (12), 3112-3121
- https://doi.org/10.1016/j.molimm.2007.02.004
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Anti-OX40 (CD134) Administration to Nonhuman Primates: Immunostimulatory Effects and Toxicokinetic StudyJournal of Immunotherapy, 2006
- OX40 ligand shuts down IL-10-producing regulatory T cellsProceedings of the National Academy of Sciences of the United States of America, 2006
- Triggering of OX40 (CD134) on CD4+CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITRBlood, 2005
- Anti-tumour therapeutic efficacy of OX40L in murine tumour modelVaccine, 2004
- Functional expression of CD134 by neutrophilsEuropean Journal of Immunology, 2004
- T-Cell Activation Marker Expression on Tumor-Infiltrating Lymphocytes As Prognostic Factor in Cutaneous Malignant MelanomaClinical Cancer Research, 2004
- Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154European Journal of Immunology, 2001
- Regression of Human Mammary Adenocarcinoma by Systemic Administration of a Recombinant Gene Encoding the hFlex-TRAIL Fusion ProteinMolecular Therapy, 2001
- OX-40: life beyond the effector T cell stageSeminars in Immunology, 1998
- Structural characteristics of CD40 ligand that determine biological functionSeminars in Immunology, 1994